Defendant
1 case as defendant.
QIAGEN Sciences LLC is a U.S. subsidiary of QIAGEN N.V., a German-founded multinational provider of sample and assay technologies. The parent company, QIAGEN N.V., was established in 1984 and is publicly traded on the Nasdaq (QGEN) and Frankfurt Stock Exchange. QIAGEN N.V.'s global corporate headquarters are in Venlo, The Netherlands, with main operative headquarters in Hilden, Germany. QIAGEN Sciences LLC maintains a manufacturing and research and development headquarters in Germantown, Maryland, United States. As of June 2025, QIAGEN N.V. employed approximately 5,700 people and reported a trailing twelve-month revenue of $2.1 billion as of March 2026.
The company develops, manufactures, and markets molecular testing systems, sample and assay technologies, and bioinformatics software. Its solutions are utilized across molecular diagnostics, applied testing (including forensics and food safety), academic research, and pharmaceutical research. Key offerings include products and automated solutions for isolating DNA, RNA, and proteins, as well as technologies for PCR, digital PCR, next-generation sequencing (NGS) workflows, and bioinformatics software for data analysis. Major platforms include QuantiFERON for tuberculosis testing, QIAstat-Dx for syndromic testing, and QIAcuity for digital PCR.
In terms of patent litigation, QIAGEN Sciences LLC primarily operates as an operating company defending against infringement claims. The company is currently tracked as a defendant in one case, Tecan Genomics Inc v. QIAGEN Sciences LLC, filed in the Delaware District Court on October 6, 2023. This posture is further supported by past litigation, such as Laboratory Corporation of America Holdings v. Qiagen Sciences, LLC, where the Federal Circuit in 2025 reversed earlier findings of willful infringement against QIAGEN Sciences, LLC related to DNA sample preparation kits.
Beyond defending, QIAGEN Sciences LLC has also demonstrated an active role in challenging intellectual property, as evidenced by its filing of an Inter Partes Review (IPR2025-00028) against Tecan Group AG on October 9, 2024. The case with Tecan Genomics Inc. involves alleged patent infringement related to nucleic acid enrichment, sequencing library preparation, and the identification of duplicate reads.
This district court case was filed by Tecan Genomics Inc against QIAGEN Sciences LLC in the Delaware District Court on October 6, 2023. It concerns US patent 10876108 and is currently active.